If you have a drug that is USD100 for one course of therapy, and you know that you can charge USD100,000, what should shareholders think when you say, 'I'd rather not take the heat'?

Quote

“If you have a drug that is USD100 for one course of therapy, and you know that you can charge USD100,000, what should shareholders think when you say, 'I'd rather not take the heat'?”